Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Sep 09, 2023 11:51am
226 Views
Post# 35627642

reassurance

reassurance
As much as I have low faith in the company management, the one thing that reassures me is that the science and intellectual property is worth more than the market cap of 49million. I continue to be greatful for the phase 1b example that showed Ruvidar is effective enough to cure 2 out of 3 patients in one treatment. No immunotherapy drug has that ability.

By way of recap:
the 2 patients cured in the phase 1b had the following profiles.
patient 1
- 12 prior HCG treatment, 2 different tumour locations on the bladder wall.
patient 2
- 18 prior treatments, 3 different tumour locations on the bladder wall.

So the drug had to reach 5 different tumours and ablate them completely. It did so and those patients have stayed NMIBC free ever since.

A drug/device that can do that is worth more than 49 million market cap.

The fact that the share price and working cash flow are the way they are is fully due to management decisions. And so I continue to hold and support the science while remaining disappointed in the management.
<< Previous
Bullboard Posts
Next >>